Open access · OA
via Europe PMC
Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes.
Cozma D, Văcărescu C, Stoicescu C.
Biomedicines · 2025 · ▲ 2 citations
Abstract
Obesity remains a major global health challenge, with glucagon-like peptide-1 receptor agonists (GLP-1RAs) providing substantial yet sensitive benefits in weight reduction, glycemic control, and cardiovascular protection. Despite robust trial data, real-world persistence is limited by cost, tolerability, and hedonic adaptation. Intermittent fasting and time-restricted eating offer physiologically complementary, low-cost strategies that enhance fat oxidation, insulin sensitivity, and metabolic flexibility while engaging behavioral mechanisms of self-control and dietary regularity. This narrative review synthesizes current evidence and proposes a pragmatic, phased framework integrating GLP-1RA therapy with structured intermittent fasting and protein-optimized nutrition. The model emphasizes sequential initiation, transition, and maintenance phases designed to align pharmacologic appetite suppression with lifestyle-driven metabolic remodeling. Mechanistically, GLP-1RAs target vascular and neuroendocrine pathways, whereas fasting activates nutrient-sensing networks (AMPK, mTOR(definition), sirtuins) associated with autophagy(definition) and longevity. Combined application may preserve lean mass, improve psychological autonomy, and reduce healthcare costs. Future research should validate this hybrid strategy in randomized trials assessing long-term weight durability, functional outcomes, and cost-effectiveness. By uniting pharmacologic potency with behavioral sustainability, phased GLP-1-fasting integration may represent an effective, affordable, and longevity-oriented paradigm for metabolic health.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3390/biomedicines13123079
- Canonical
- link ↗
- Fetched
- 2026-07-01 MST
Cite this
APA
D, C., C, V., & C., S. (2025). Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes. <em>Biomedicines</em>. https://doi.org/10.3390/biomedicines13123079
Vancouver
D C, C V, C. S. Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes. Biomedicines. 2025. doi:10.3390/biomedicines13123079.
BibTeX
@article{cozma2025AddedV,
title = {Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes.},
author = {Cozma D and Văcărescu C and Stoicescu C.},
journal = {Biomedicines},
year = {2025},
doi = {10.3390/biomedicines13123079},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Circulation Research 2018
Open access · OA
Sirtuins and NAD + in the Development and Treatment of Metabolic and Cardiovascular Diseases
Diabetes 2008
Open access · CC-BY
Activation of Estrogen Receptor Is Crucial for Resveratrol-Stimulating Muscular Glucose Uptake via Both Insulin-Dependent and -Independent Pathways
Medicina 2026
Open access · CC-BY
Metabolic and Neuroendocrine Responses to Intermittent Fasting in Obesity
Diabetes Metabolic Syndrome and Obesity 2014
Open access · CC-BY
AMPK activation: a therapeutic target for type 2 diabetes?
International Journal of Science and Research (IJSR) 2025
Open access · CC-BY
Intermittent Fasting-Impacts on Metabolic Health and Longevity
Science 1997
Citation only